文献速递消化系统肿瘤

靶向质谱精准识别胰腺癌囊性前驱病变:IIc期诊断研究

Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study.
PubMed 文献 · J Clin Oncol · 2017-11-22

该IIc期诊断研究采用超声内镜引导下抽吸的囊液,通过靶向质谱定量检测标志物肽段。在68例验证队列中,黏蛋白5AC和黏蛋白2肽段组合区分癌前/恶性与良性病变的准确率达97%,优于癌胚抗原和细胞学;黏蛋白5AC联合前列腺干细胞抗原识别高级别不典型增生/癌的准确率达96%。

要点

  • 囊液黏蛋白5AC和黏蛋白2肽段组合区分癌前/恶性与良性病变准确率97%。
  • 该组合准确率优于囊液癌胚抗原的61%和细胞学的84%。
  • 黏蛋白5AC联合前列腺干细胞抗原识别高级别不典型增生/癌准确率96%。

核心结论

  • 仅检测三种囊液生物标志物的靶向质谱分析可高准确度识别和评估胰腺腺癌的囊性前驱病变。

研究设计与样本

  • IIc期诊断研究,囊液样本来自常规超声内镜引导下抽吸。
  • 探索性蛋白质组学在24例队列中鉴定8个候选生物标志物。
  • 采用30条重标肽段和并行反应监测质谱定量,在80例训练队列测试,并在68例验证队列前瞻性评估。
  • 终点为手术病理诊断或临床随访,诊断评估对质谱结果设盲。

主要发现

  • 验证队列中,黏蛋白5AC和黏蛋白2肽段组合区分癌前/恶性与良性病变的准确率为97%(95%CI,89%至99%)。
  • 囊液癌胚抗原区分癌前/恶性与良性病变的准确率为61%(95%CI,46%至74%;P < .001),细胞学为84%(95%CI,71%至92%;P = .02)。
  • 黏蛋白5AC联合前列腺干细胞抗原识别高级别不典型增生/癌的准确率为96%(95%CI,90%至99%),检出95%的恶性/重度不典型增生病变。
  • 癌胚抗原和细胞学分别检出35%和50%的恶性/重度不典型增生病变(P < .001和P = .003)。

临床怎么用

  • 对超声内镜引导下抽吸的囊液可行靶向质谱检测三种生物标志物,辅助鉴别胰腺囊性病变的癌前/恶性潜能。
  • 黏蛋白5AC和黏蛋白2肽段组合可用于区分癌前/恶性与良性病变,黏蛋白5AC联合前列腺干细胞抗原可用于识别高级别不典型增生/癌。

局限性

  • 需进一步研究确定该方法能否促进及时诊断癌症、成功干预和预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Pancreatic cystic lesions are common incidental findings on imaging, but up to half may be forerunners of pancreatic cancer. Therefore, accurate differential diagnosis is crucial for correct patient management. Unfortunately, currently available diagnostic methods cannot robustly identify premalignant and malignant pancreatic cystic lesions. Methods Cyst fluid samples obtained by routine endoscopic ultrasound-guided aspiration were used for the analyses. In a cohort of 24 patients, eight biomarker candidates for malignant potential and high-grade dysplasia/cancer were identified by an explorative proteomic approach. Subsequently, a quantitative analysis, using 30 heavy-labeled peptides from the biomarkers and parallel reaction monitoring mass spectrometry, was devised, tested in a training cohort of 80, and prospectively evaluated in a validation cohort of 68 patients. End points were surgical pathology diagnosis/clinical follow-up. Diagnostic assessments were blinded to mass spectrometry results. Results The optimal set of markers for detecting malignant potential was a panel of peptides from mucin-5AC and mucin-2, which could discriminate premalignant/malignant lesions from benign with an accuracy of 97% (95% CI, 89% to 99%) in the validation cohort. This result compared favorably with the accuracy of standard analyses: cyst fluid carcinoembryonic antigen (61%; 95% CI, 46% to 74%; P < .001) and cytology (84%; 95% CI, 71% to 92%; P = .02). A combination of proteins mucin-5AC and prostate stem-cell antigen could identify high-grade dysplasia/cancer with an accuracy of 96% (95% CI, 90% to 99%), and detected 95% of malignant/severely dysplastic lesions, compared with 35% and 50% for carcinoembryonic antigen and cytology ( P < .001 and P = .003, respectively). Conclusion Targeted mass spectrometry analysis of just three cyst fluid biomarkers provides highly accurate identification and assessment of cystic precursors to pancreatic adenocarcinoma. Additional studies should determine whether the method can facilitate timely cancer diagnosis, successful intervention, and prevention.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jabbar KS, Arike L, Verbeke CS, et al. Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study. J Clin Oncol. 2017. PMID: 29166170. doi:10.1200/JCO.2017.73.7288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。